Last reviewed · How we verify
HCP1004
HCP1004 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.
HCP1004 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC).
At a glance
| Generic name | HCP1004 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Androgen receptor degrader (SARD) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HCP1004 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide more complete suppression of androgen receptor-driven disease.
Approved indications
- Castration-resistant prostate cancer (CRPC)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (PHASE3)
- Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCP1004 CI brief — competitive landscape report
- HCP1004 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI